EGFR/HER-targeted therapeutics in ovarian cancer

Future Medicinal Chemistry

Volumn 4, Issue 4, 2012, Pages 447-469

  Wilken, Jason A ^a   Badri, Tayf ^a   Cross, Sarah ^a   Raji, Rhoda ^a   Santin, Alessandro D ^a   Schwartz, Peter ^a   Branscum, Adam J ^b   Baron, Andre T ^c   Sakhitab, Adam I ^a   Maihle, Nita J ^a,d,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d YALE UNIVERSITY   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AC 480; AFATINIB; ARRY 380; ARRY 543; CANERTINIB; CETUXIMAB; CP 724714; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HKI 357; LAPATINIB; MATUZUMAB; MUBRITINIB; NERATINIB; PANITUMUMAB; PD 183085; PELITINIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARLITINIB; XL 647;

CANCER CELL; DRUG TARGETING; HUMAN; IN VITRO STUDY; MULTIPLE CYCLE TREATMENT; OVARY; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

EID: 84858671737     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.11     Document Type: Review

References (285)

1. Siegel R, Naishadham D, Hemal A. Cancer statistics. CA Cancer J. Clin. 62(1), 10-29 (2012).
2. Rodland KD, Maihle NJ. Searching for a system: the quest for ovarian cancer biomarkers. Cancer Biomark. 8(4-5), 223-230 (2011).
3. Barrena Medel NI, Wright JD, Herzog TJ. Targeted therapies in epithelial ovarian cancer. J. Oncol. doi:10.1155/2010/314326 (2010) (Epub ahead of print).
4. Siwak DR, Carey M, Hennessy BT et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J. Oncol. doi:10.1155/2010/568938 (2010) (Epub ahead of print).
5. Zeineldin R, Muller CY, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. J. Oncol. doi:10.1155/2010/414676 (2010) (Epub ahead of print).
6. Vasey PA. Ovarian cancer: frontline standard treatment in 2008. Annu. Oncol. 19(Suppl. 7), vii61-66 (2008).
7. Wakabayashi MT, Lin PS, Hakim AA. The role of cytoreductive/debulking surgery in ovarian cancer. J. Natl Compr. Canc. Netw. 6(8), 803-810 (2008).
8. Lin H, Changchien CC. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches. Taiwan J. Obstet. Gynecol. 46(4), 379-388 (2007).
9. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 903-913 (2004). (Pubitemid 38221150)
10. Burgess AW, Cho HS, Eigenbrot C et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12(3), 541-552 (2003). (Pubitemid 37222478)
11. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410(1), 83-86 (1997). (Pubitemid 27283389)
12. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell. Biol. 7(7), 505-516 (2006). (Pubitemid 44036456)
13. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol. Cell. Biol. 19(10), 6845-6857 (1999). (Pubitemid 29441868)
14. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1), 2-16 (2006). (Pubitemid 43199589)
15. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 19(13), 3159-3167 (2000). (Pubitemid 30428195)
16. Boerner JL, Danielsen A, Maihle NJ. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp. Cell Res. 284(1), 111-121 (2003). (Pubitemid 36331970)
17. Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL. Muc4- ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol. Cell. Biol. 17(7), 2931-2941 (2006). (Pubitemid 43993498)
18. Price-Schiavi SA, Andrechek E, Idris N et al. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4-(sialomucin complex) in rat mammary gland during pregnancy. J. Cell. Physiol. 203(1), 44-53 (2005). (Pubitemid 40328171)
19. Carraway KL, Carvajal ME, Li P, Carraway CA. ErbB2 and its ligand Muc4 (sialomucin complex) in rat lacrimal gland. Adv. Exp. Med. Biol. 506(Pt A), 289-295 (2002). (Pubitemid 36307683)
20. Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2(3), 176-183 (2000). (Pubitemid 32223582)
21. Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 1785(2), 232-265 (2008).
22. Basu A, Raghunath M, Bishayee S, Das M. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol. Cell. Biol. 9(2), 671-677 (1989). (Pubitemid 19038870)
23. Wilken JA, Baron AT, Foty RA, McCormick DJ, Maihle NJ. Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor (sEGFR) and a5-integrin. Biochemistry 50(20), 4309-4321 (2011).
24. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Annu. Oncol. 12(6), 745-760 (2001). (Pubitemid 32655082)
25. Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55(23), 5536-5539 (1995).
26. Lassus H, Sihto H, Leminen A et al. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J. Mol. Med. 84(8), 671-681 (2006). (Pubitemid 44164262)
27. de Graeff P, Crijns AP, Ten Hoor KA et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br. J. Cancer 99(2), 341-349 (2008).
28. Steffensen KD, Waldstrom M, Olsen DA et al. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin. Cancer Res. 14(11), 3278-3282 (2008).
29. Pedersen K, Angelini PD, Laos S et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 29(12), 3319-3331 (2009).
30. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res. 71(5), 1515-1519 (2011).
31. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8(11), 2917-2923 (1993). (Pubitemid 23312894)
32. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. Biol. Chem. 266(3), 1716-1720 (1991). (Pubitemid 21908361)
33. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59(6), 1196-1201 (1999). (Pubitemid 29136246)
34. Anido J, Scaltriti M, Bech Serra JJ et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25(13), 3234-3244 (2006). (Pubitemid 44106773)
35. Liu CY, Yang W, Li JF, Sun SL, Shou CC. Effect of trastuzumab on tumor cell lines shedding high or low level of HER-2 ECD. Zhonghua Zhong Liu Za Zhi 29(2), 101-105 (2007).
36. Christianson TA, Doherty JK, Lin YJ et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58(22), 5123-5129 (1998). (Pubitemid 28521172)
37. Maruo T, Ladines-Llave CA, Samoto T et al. Expression of epidermal growth factor and its receptor in the human ovary during follicular growth and regression. Endocrinology 132(2), 924-931 (1993). (Pubitemid 23056159)
38. Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 7(7), 1273-1278 (1992).
39. Baron AT, Lafky JM, Suman VJ et al. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol. Biomarkers Prev. 10(11), 1175-1185 (2001). (Pubitemid 33064306)
40. Lafky JM, Baron AT, Cora EM et al. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res. 65(8), 3059-3062 (2005). (Pubitemid 40524585)
41. Berchuck A, Rodriguez GC, Kamel A et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol. 164(2), 669-674 (1991).
42. Foekens JA, Van Putten WL, Portengen H et al. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF- 1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J. Steroid Biochem. Mol. Biol. 37(6), 815-821 (1990).
43. Janinis J, Nakopoulou L, Panagos G, Davaris P. Immunohistochemical expression of EGF-R in malignant surface epithelial ovarian neoplasms (SEON). Eur. J. Gynaecol. Oncol. 15(1), 19-23 (1994). (Pubitemid 24120609)
44. Leng J, Lang J, Shen K, Guo L. Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin. Med. Sci. J. 12(2), 67-70 (1997).
45. Psyrri A, Kassar M, Yu Z et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin. Cancer Res. 11(24 Pt 1), 8637-8643 (2005). (Pubitemid 43005911)
46. Skirnisdottir I, Seidal T, Sorbe B. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging. Int. J. Gynecol. Cancer 14(2), 259-270 (2004). (Pubitemid 38533897)
47. Baekelandt M, Kristensen GB, Trope CG, Nesland JM, Holm R. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res. 19(5C), 4469-4474 (1999). (Pubitemid 30042808)
48. Elie C, Geay JF, Morcos M et al. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br. J. Cancer 91(3), 470-475 (2004). (Pubitemid 39093565)
49. Ferrandina G, Ranelletti FO, Lauriola L et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/ neu expression in ovarian cancer. Gynecol. Oncol. 85(2), 305-310 (2002). (Pubitemid 34522990)
50. Goff BA, Muntz HG, Greer BE, Tamimi HK, Gown AM. Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet. Gynecol. 92(1), 88-93 (1998). (Pubitemid 28285327)
51. Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol. Oncol. 70(3), 378-385 (1998). (Pubitemid 28473638)
52. Lee CH, Huntsman DG, Cheang MC et al. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int. J. Gynecol. Pathol. 24(2), 147-152 (2005). (Pubitemid 40389539)
53. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int. J. Gynecol. Cancer 14(6), 1086-1096 (2004). (Pubitemid 39603351)
54. Raspollini MR, Castiglione F, Garbini F et al. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int. J. Surg. Pathol. 13(2), 135-142 (2005). (Pubitemid 40617540)
55. Skirnisdottir I, Seidal T, Karlsson MG, Sorbe B. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int. J. Oncol. 26(1), 177-183 (2005).
56. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707-712 (1989). (Pubitemid 19147683)
57. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 75(8), 2147-2152 (1995).
58. Kupryjanczyk J, Madry R, Plisiecka-Halasa J et al. TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br. J. Cancer 91(11), 1916-1923 (2004). (Pubitemid 40065521)
59. Meden H, Marx D, Roegglen T, Schauer A, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int. J. Gynecol. Pathol. 17(1), 61-65 (1998). (Pubitemid 28016704)
60. Nijman HW, Kenemans P, Poort-Keesom RJ et al. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 83(2), 201-206 (1999). (Pubitemid 29164429)
61. Davidson B, Gotlieb WH, Ben-Baruch G et al. E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol. Oncol. 79(3), 362-371 (2000).
62. Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50(13), 4087-4091 (1990). (Pubitemid 20225635)
63. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Annu. Oncol. 15(1), 104-112 (2004). (Pubitemid 38145531)
64. Lassus H, Leminen A, Vayrynen A et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol. Oncol. 92(1), 31-39 (2004). (Pubitemid 38147368)
65. Coronado Martin PJ, Fasero Laiz M, Garcia Santos J, Ramirez Mena M, Vidart Aragon JA. Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer. Med. Clin. (Barc.) 128(1), 1-6 (2007). (Pubitemid 46232725)
66. Hogdall EV, Christensen L, Kjaer SK et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98(1), 66-73 (2003). (Pubitemid 36741127)
67. Meden H, Marx D, Rath W et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int. J. Gynecol. Pathol. 13(1), 45-53 (1994). (Pubitemid 24006333)
68. Tomic S, Ilic Forko J, Babic D, Sundov D, Kuret S, Andelinovic S. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma. Croat. Med. J. 44(4), 429-434 (2003). (Pubitemid 37092801)
69. Verri E, Guglielmini P, Puntoni M et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 68(2-3), 154-161 (2005). (Pubitemid 41158970)
70. Protopapas A, Diakomanolis E, Bamias A et al. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. Eur. J. Gynaecol. Oncol. 25(2), 225-229 (2004). (Pubitemid 38268704)
71. Raspollini MR, Amunni G, Villanucci A et al. HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl. Immunohistochem. Mol. Morphol. 14(2), 181-186 (2006). (Pubitemid 43941182)
72. Surowiak P, Materna V, Kaplenko I et al. Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol. Histopathol. 21(7), 713-720 (2006). (Pubitemid 44082713)
73. Castellvi J, Garcia A, Rojo F et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107(8), 1801-1811 (2006). (Pubitemid 44582949)
74. Haldane JS, Hird V, Hughes CM, Gullick WJ. c-erbB-2 oncogene expression in ovarian cancer. J. Pathol. 162(3), 231-237 (1990).
75. Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol. Oncol. 44(3), 245-253 (1992).
76. Leeson SC, Morphopoulos G, Buckley CH, Hale RJ. c-erbB-2 oncogene expression in Stage I epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 102(1), 65-67 (1995).
77. Peethambaram PP, Cliby WA, Lubiniecki G et al. Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. Gynecol. Oncol. 89(1), 99-104 (2003). (Pubitemid 36403654)
78. Rodriguez-Burford C, Chhieng DC, Stockard CR et al. p53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian carcinomas. Dis. Markers 19(1), 11-17 (2003). (Pubitemid 38125651)
79. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 73(5), 1456-1459 (1994). (Pubitemid 24072553)
80. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am. J. Obstet. Gynecol. 168(1 Pt 1), 162-169 (1993). (Pubitemid 23047634)
81. Singleton TP, Perrone T, Oakley G et al. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. Cancer 73(5), 1460-1466 (1994). (Pubitemid 24072554)
82. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int. J. Gynecol. Cancer 11(2), 119-129 (2001). (Pubitemid 32381660)
83. Van der Zee AG, Hollema H, Suurmeijer AJ et al. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J. Clin. Oncol. 13(1), 70-78 (1995).
84. Shen K, Lang J, Guo L. Overexpression of C-erbB3 in transitional cell carcinoma of the ovary. Zhonghua Fu Chan Ke Za Zhi 30(11), 658-661 (1995).
85. Tanner B, Hasenclever D, Stern K et al. ErbB-3 predicts survival in ovarian cancer. J. Clin. Oncol. 24(26), 4317-4323 (2006). (Pubitemid 46630790)
86. Gilmour LM, Macleod KG, McCaig A, Gullick WJ, Smyth JF, Langdon SP. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res. 61(5), 2169-2176 (2001). (Pubitemid 32692043)
87. Lafky JM, Greenwood T, Baron AT, Boardman CH, Cora EM, Maihle NJ. Soluble ErbB receptors (sEGFR/sErbBs): serum biomarkers in breast and ovarian cancer. In: Tumor Markers: Physiology, Pathobiology, Technology and ClinicalApplications. Diamandis EP (Ed.). AACC Press, Chicago, IL, USA, 427-431 (2002).
88. Maihle NJ, Baron AT, Barrette BA et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 107, 247-258 (2002).
89. Kim YS, Alarcon SV, Lee S et al. Update on Hsp90 inhibitors in clinical trial. Current Top. Med. Chem. 9(15), 1479-1492 (2009).
90. Fry DW, Kraker AJ, McMichael A et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265(5175), 1093-1095 (1994). (Pubitemid 24293076)
91. Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13(4), 365-373 (2008). (Pubitemid 351446197)
92. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4), 317-328 (2004). (Pubitemid 38482068)
93. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2- positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94(2), 259-267 (2006). (Pubitemid 43151545)
94. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18(13), 2241-2251 (1999). (Pubitemid 29186925)
95. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001). (Pubitemid 32222155)
96. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 53(1), 94-100 (1993). (Pubitemid 23019382)
97. Weiner LM, Holmes M, Richeson A et al. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J. Immunol. 151(5), 2877-2886 (1993). (Pubitemid 23264540)
98. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120(4), 781-787 (2007). (Pubitemid 46175397)
99. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8), 1275-1280 (2007). (Pubitemid 46993549)
100. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41(3), 697-706 (1985).
101. Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl Acad. Sci. USA 92(8), 3353-3357 (1995).
102. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB- 2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60(13), 3384-3388 (2000). (Pubitemid 30482151)
103. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit. Rev. Oncol. Hematol. 68(2), 93-106 (2008).
104. Assoian RK, Zhu X. Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. Curr. Opin. Cell Biol. 9(1), 93-98 (1997). (Pubitemid 27065114)
105. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol. Endocrinol. 12(7), 941-953 (1998). (Pubitemid 30660662)
106. Delord JP, Allal C, Canal M et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Annu. Oncol. 16(12), 1889-1897 (2005). (Pubitemid 41724277)
107. Qiu L, Zhou C, Sun Y et al. Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation. Int. J. Oncol. 29(4), 1003-1011 (2006).
108. Cao C, Lu S, Sowa A et al. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett. 266(2), 249-262 (2008).
109. Ji C, Cao C, Lu S et al. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother. Pharmacol. 62(5), 857-865 (2008).
110. Zhou C, Qiu L, Sun Y et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int. J. Oncol. 29(1), 269-278 (2006).
111. Henic E, Sixt M, Hansson S, Hoyer-Hansen G, Casslen B. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecol. Oncol. 101(1), 28-39 (2006).
112. Yue P, Zhang X, Paladino D et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene doi:10.1038/onc.2011.409 (2011) (Epub ahead of print).
113. Caputo R, Bianco R, Damiano V et al. ZD1839 ('Iressa'), a selective EGFR tyrosine kinase inhibitor, inhibits growth factor production and angiogenesis in human cancer cells. Annals Oncology 12(Suppl. 4), 93 (2001).
114. Park SJ, Kim MJ, Kim HB et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem. Pharmacol. 77(8), 1328-1336 (2009).
115. Canal Sr. PR, Delord JP, Quideau S et al. Cross-talk between PTEN and RhoB drives biological effect of trastuzumab in ovarian cancer. Proc. Am. Assoc. Cancer Res. 50, (Abstract 1843) (2009).
116. Mukherji M, Brill LM, Ficarro SB, Hampton GM, Schultz PG. A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways. Biochemistry 45(51), 15529-15540 (2006). (Pubitemid 46043111)
117. Wilken JA, Webster KT, Maihle NJ. Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. J. Ovarian Res. 3(1), 7 (2010).
118. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20(21), 4292-4302 (2002). (Pubitemid 35266289)
119. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol. 20(9), 2240-2250 (2002). (Pubitemid 34441651)
120. Vergote IB, Humblet Y, Van Cutsem E et al. A multicenter Phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: interim data. J. Clin. Oncol. 23(16S), 3162 (2005).
121. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermalgrowth factor receptor mutations and immunohistochemical expression: a gynacologic oncology group study. Clin. Cancer Res. 11(15), 5539-5548 (2005). (Pubitemid 41060831)
122. Posadas EM, Liel MS, Kwitkowski V et al. A Phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 109(7), 1323-1330 (2007). (Pubitemid 46466559)
123. Blank SV, Christos P, Curtin JP et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a Phase II study based on surgical reassessment. Gynecol. Oncol. 119(3), 451-456 (2010).
124. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96(22), 1682-1691 (2004). (Pubitemid 39585637)
125. Hirte H, Oza A, Swenerton K et al. A Phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). Gynecol. Oncol. 118(3), 308-312 (2010).
126. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006). (Pubitemid 46630933)
127. Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/ EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int. J. Gynecol. Cancer 15(5), 785-792 (2005). (Pubitemid 41783082)
128. Finkler N, Gordon A, Crozier M et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 20, 831 (2001).
129. Joly F, Weber B, Pautier P et al. Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after first line of platinum-based chemotherapy: A french FEDEGYN-FNCLCC Phase II trial. J. Clin. Oncol. 27(15s), Abstract 5555 (2009).
130. Weroha SJ, Oberg AL, Ziegler KL et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol. Oncol. 122(1), 116-120 (2011).
131. Rivkin SE, Moon J, Muller C, Iriarte D, Arthur J, Reid H. A Phase I/II study of lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients or stage IV breast cancer patients. Presented at: 7th Biennial Ovarian Cancer Res. Symposium. Seattle, WA, USA 25 October 2008.
132. Rivkin SE, Muller C, Iriarte D, Arthur J, Canoy A, Reid H. Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients. J. Clin. Oncol. 26, 5556 (2008).
133. Garcia AA, Sill MW, Lankes HA et al. A Phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol. Oncol. 124(3), 569-574 (2011).
134. Campos S, Hamid O, Seiden MV et al. Multicenter, randomized Phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J. Clin. Oncol. 23(24), 5597-5604 (2005).
135. Annunziata CM, Walker AJ, Minasian L et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin. Cancer Res. 16(2), 664-672 (2010).
136. VanUmmersen L, MNess E, Goldstein DJ et al. A Phase I trial of SU101 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 15, 740 (1997).
137. Rosen L, Lopez AM, Mulay M et al. A Phase I/II study of SU101 in patients with ovarian, prostate, and non-small cell lung cancers. Proc. Am. Soc. Clin. Oncol. 15, 739 (1997).
138. Chap L, Chachoua A, Lopez A, DePaoli A, Hannah AL. A Phase II study of SU101 in patents with advanced ovarian cancer. Proc. Am. Soc. Clin. Oncol. 17, 1437 (1999).
139. Secord AA, Blessing JA, Armstrong DK et al. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecol. Oncol. Group study. Gynecol. Oncol. 108(3), 493-499 (2008).
140. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int. J. Gynecol. Cancer 15(Suppl. 1), 36-41 (2005). (Pubitemid 40696476)
141. Schilder RJ, Pathak HB, Lokshin AE et al. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol. Oncol. 113(1), 21-27 (2009).
142. Seiden MV, Burris HA, Matulonis U et al. A Phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol. 104(3), 727-731 (2007).
143. Ray-Coquard I, Guastalla JP, Allouache D et al. HER2 overexpression/ amplification and trastuzumab treatment in advanced ovarian cancer: a GINECO Phase II study. Clin. Ovarian Cancer 1(1), 54-59 (2008).
144. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36(2), 207-211 (1990). (Pubitemid 20061287)
145. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9(3), 389-393 (1991).
146. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecol. Oncol. Group. J. Clin. Oncol. 21(2), 283-290 (2003). (Pubitemid 46606157)
147. McAlpine JN, Wiegand KC, Vang R et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9, 433 (2009).
148. Makhija S, Amler LC, Glenn D et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J. Clin. Oncol. 28(7), 1215-1223 (2009).
149. Kaye SB, Poole CJ, Bidzinksi M et al. A randomised Phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J. Clin. Oncol. 26, 5520 (2008).
150. Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23(11), 2534-2543 (2005). (Pubitemid 47050843)
151. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24(26), 4324-4332 (2006). (Pubitemid 46630791)
152. Herbst RS, Lippman SM. Molecular signatures of lung cancer - toward personalized therapy. N. Engl. J. Med. 356(1), 76-78 (2007). (Pubitemid 46041757)
153. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annu. Oncol. 22(8), 1736-1747 (2011).
154. Christensen CM. The Innovator's Prescription: a Disruptive Solution for Health Care. Christensen CM, Grossman JH, Hwang J (Eds). McGraw-Hill, NY, USA (2009).
155. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl Acad. Sci. USA 95(2), 652-656 (1998). (Pubitemid 28083798)
156. Thaker PH, Han LY, Kamat AA et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12(8), 939-944 (2006). (Pubitemid 44175146)
157. Burger RA, Brady MF, A BM et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), and fallopian tube cancer (FTC): a Gynecol. Oncol. Group study. Oncology. 79(1-2), 98-104 (2010).
158. Konner J, Schilder RJ, DeRosa FA et al. A Phase II study of cetuximab/paclitaxel/ carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol. Oncol. 110(2), 140-145 (2008).
159. Vasey PA, Gore M, Wilson R et al. A Phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br. J. Cancer 98(11), 1774-1780 (2008). (Pubitemid 351748839)
160. Nimeiri HS, Oza AM, Morgan RJ et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol. 110(1), 49-55 (2008).
161. Hensley ML. Big costs for little gain in ovarian cancer. J. Clin. Oncol. 29(10), 1230-1232 (2011).
162. Jorgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer. Oncologist 12(4), 397-405 (2007). (Pubitemid 46698717)
163. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. New Engl. J. Med. 358(13), 1409-1411 (2008). (Pubitemid 351468442)
164. Bengala C, Bettelli S, Bertolini F et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Annu. Oncol. 20(3), 469-474 (2008).
165. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67(6), 2643-2648 (2007). (Pubitemid 46548951)
166. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97(8), 1139-1145 (2007). (Pubitemid 47587019)
167. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
168. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 128(2), 225-231 (2007). (Pubitemid 46123521)
169. Jain A, Penuel E, Mink S et al. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 70(5), 1989-1999 (2010).
170. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in 'resistant' breast carcinoma cells. Cancer Res. 69(6), 2191-2194 (2009).
171. Domont J, Besse B, Valent A et al. Assessment of response to gefitinib in combination with chemotherapy in ovarian cancer according to EGFR expresion in monocentric study. Annu. Oncol. 17(Suppl. 9), 176 (2006).
172. Lacroix L, Pautier P, Duvillard P et al. Response of ovarian carcinomas to gefitinib-carboplatin- paclitaxel-combination is not associated with EGFR kinase domain somatic mutations. Int. J. Cancer 118(4), 1068-1069 (2006). (Pubitemid 43157690)
173. Pautier P, Joly F, Kerbrat P et al. Phase II study of gefitinib- n combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol. Oncol. 116(2), 157-162 (2010).
174. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101(19), 1308-1324 (2009).
175. Wilken JA, Baron AT, Maihle NJ. The epidermal growth factor receptor conundrum. Cancer 117(11), 2358-2360 (2010).
176. Van der Veeken J, Oliveira S, Schiffelers RM, Storm G, Van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr. Cancer Drug Targets 9(6), 748-760 (2009).
177. Mueller KL, Yang ZQ, Haddad R, Ethier SP, Boerner JL. EGFR/Met association regulates EGFR TKI resistance in breast cancer. J. Mol. Signal. 5, 8 (2010).
178. Bill HM, Knudsen B, Moores SL et al. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol. Cell. Biol. 24(19), 8586-8599 (2004). (Pubitemid 39245079)
179. Marcoux N, Vuori K. EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2. Oncogene 22(38), 6100-6106 (2003). (Pubitemid 37175888)
180. Tiganis T, Kemp BE, Tonks NK. The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling. J. Biol. Chem. 274(39), 27768-27775 (1999).
181. Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J. Cell Biol. 183(1), 143-155 (2008).
182. Norambuena A, Metz C, Jung JE et al. Phosphatidic acid induces ligand-independent epidermal growth factor receptor endocytic traffic through PDE4 activation. Mol. Cell. Biol. 21(16), 2916-2929 (2010).
183. Grushko TA, Blackwood MA, Schumm PL et al. Molecular-cytogenetic analysis of HER-2/ neu gene in BRCA1-associated breast cancers. Cancer Res. 62(5), 1481-1488 (2002). (Pubitemid 34407811)
184. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211(1), 26-35 (2007). (Pubitemid 46092026)
185. Folkins AK, Jarboe EA, Saleemuddin A et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 109(2), 168-173 (2008).
186. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl Acad. Sci. USA 108(18), 7547-7552 (2011).
187. Seton-Rogers S. Ovarian cancer: model building. Nat. Rev. Cancer 11(6), 386 (2011).
188. Wang DP, Fujii S, Konishi I et al. Expression of c-erbB-2 protein and epidermal growth factor receptor in normal tissues of the female genitaltract and in the placenta. Virchows Arch. A Pathol. Anat. Histopathol. 420(5), 385-393 (1992).
189. Lei ZM, Rao CV. Expression of epidermal growth factor (EGF) receptor and its ligands, EGF and transforming growth factor-alpha, in human fallopian tubes. Endocrinology 131(2), 947-957 (1992).
190. el-Danasouri I, Frances A, Westphal LM. Immunocytochemical localization of transforming growth factor-alpha and epidermal growth factor receptor in human fallopian tubes and cumulus cells. Am. J. Reprod. Immunol. 30(2-3), 82-87 (1993). (Pubitemid 24014461)
191. Chegini N, Zhao Y, McLean FW. Expression of messenger ribonucleic acid and presence of immunoreactive proteins for epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha) and EGF/TGF alpha receptors and 125I-EGF binding sites in human fallopian tube. Biol. Reprod. 50(5), 1049-1058 (1994). (Pubitemid 24116039)
192. Adachi K, Kurachi H, Homma H et al. Estrogen induces epidermal growth factor (EGF) receptor and its ligands in human fallopian tube: involvement of EGF but not transforming growth factor-alpha in estrogen-induced tubal cell growth in vitro. Endocrinology 136(5), 2110-2119 (1995).
193. Adachi K, Kurachi H, Adachi H et al. Menstrual cycle specific expression of epidermal growth factor receptors in human fallopian tube epithelium. J. Endocrinol. 147(3), 553-563 (1995).
194. Smotrich DB, Stillman RJ, Widra EA et al. Immunocytochemical localization of growth factors and their receptors in human pre-embryos and Fallopian tubes. Hum. Reprod. 11(1), 184-190 (1996). (Pubitemid 26047695)
195. Sun XX, Gemzell-Danielsson K, Li HZ, Stabi B, Stavreus-Evers A. Expression of heparin-binding epidermal growth factor-like growth factor and its receptors in the human fallopian tube and endometrium after treatment with mifepristone. Fertil. Steril. 85(1), 171-178 (2006). (Pubitemid 43063442)
196. Pegues JC, Kannan B, Stromberg K. ErbB receptor expression and growth response to heregulin beta 1 in five ovarian carcinoma lines. Int. J. Oncol. 14(6), 1169-1176 (1999).
197. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol. 15(12), 6496-6505 (1995).
198. Lewis GD, Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37(4), 255-263 (1993). (Pubitemid 23300507)
199. Bacus SS, Gudkov AV, Zelnick CR et al. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res. 53(21), 5251-5261 (1993). (Pubitemid 23333396)
200. Dai Q, Ling YH, Lia M et al. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin. Cancer Res. 11(4), 1572-1578 (2005). (Pubitemid 40315242)
201. Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12(3), 961-971 (1993). (Pubitemid 23095845)
202. Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ('Iressa®'). Br. J. Cancer 86(3), 456-462 (2002). (Pubitemid 34185133)
203. Tang HJ, Jin X, Wang S et al. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol. Oncol. 100(2), 308-317 (2006). (Pubitemid 43078483)
204. Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem. Pharmacol. 72(8), 941-948 (2006). (Pubitemid 44376781)
205. Gilmour LM, Macleod KG, McCaig A et al. Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin. Cancer Res. 8(12), 3933-3942 (2002). (Pubitemid 35424788)
206. Gordon AW, Pegues JC, Johnson GR, Kannan B, Auersperg N, Stromberg K. mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. Cancer Lett. 89(1), 63-71 (1995).
207. Mullen P, Cameron DA, Hasmann M, Smyth JF, Langdon SP. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol. Cancer Ther. 6(1), 93-100 (2007). (Pubitemid 46206671)
208. Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff J, Cannistra SA. Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br. J. Cancer 74(3), 446-452 (1996). (Pubitemid 26254576)
209. Qiu L, Di W, Jiang Q et al. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int. J. Oncol. 27(5), 1441-1448 (2005).
210. Abuharbeid S, Apel J, Sander M et al. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV- 3 cells. Biochem. Biophys. Res. Commun. 321(2), 403-412 (2004). (Pubitemid 39055761)
211. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer 94(6), 774-782 (2001). (Pubitemid 33032823)
212. Dean GS, Pusztai L, Xu FJ et al. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin. Cancer Res. 4(10), 2545-2550 (1998). (Pubitemid 28477923)
213. Grunt TW. Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. Cancer Lett. 189(2), 147-156 (2003). (Pubitemid 35461991)
214. Lu C, Kamat AA, Lin YG et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin. Cancer Res. 13(14), 4209-4217 (2007). (Pubitemid 47105985)
215. Marth C, Cronauer MV, Doppler W, Ofner D, Ullrich A, Daxenbichler G: Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int. J. Cancer 50(1), 64-68 (1992).
216. Takai N, Jain A, Kawamata N et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104(12), 2701-2708 (2005). (Pubitemid 41798280)
217. Ciardiello F, Caputo R, Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7(5), 1459-1465 (2001). (Pubitemid 32708703)
218. Hsieh CY, Chen CA, Chou CH et al. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis. J. Biomed. Sci. 11(2), 249-259 (2004).
219. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18(3), 731-738 (1999). (Pubitemid 29080330)
220. Bull Phelps SL, Schorge JO, Peyton MJ et al. Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol. Oncol. 109(3), 411-417 (2008).
221. Itamochi H, Kigawa J, Kanamori Y et al. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potentialtreatment strategy. Mol. Cancer Ther. 6(1), 227-235 (2007). (Pubitemid 46206686)
222. Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int. J. Cancer 123(12), 2939-2949 (2008).
223. Taetle R, Honeysett JM, Houston LL. Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells. J. Natl Cancer Inst. 80(13), 1053-1059 (1988).
224. Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anticancer Drugs 13(9), 949-956 (2002). (Pubitemid 35388197)
225. Boente MP, Berchuck A, Whitaker RS et al. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/ neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. Gynecol. Oncol. 70(1), 49-55 (1998). (Pubitemid 28368874)
226. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2- p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J. Biol. Chem. 276(52), 48679-48692 (2001).
227. Caliaro MJ, Vitaux P, Lafon C et al. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br. J. Cancer 75(3), 333-340 (1997). (Pubitemid 27051046)
228. Camoratto AM, Jani JP, Angeles TS et al. CEP- 751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int. J. Cancer. 72(4), 673-679 (1997). (Pubitemid 27356171)
229. Casalini P, Botta L, Menard S. Role of p53 in HER2-induced proliferation or apoptosis. J. Biol. Chem. 276(15), 12449-12453 (2001).
230. Cassinelli G, Lanzi C, Pensa T et al. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin. Biochem. Pharmacol. 59(12), 1539-1547 (2000). (Pubitemid 30229886)
231. Chan SD, Antoniucci DM, Fok KS et al. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3. J. Biol. Chem. 270(38), 22608-22613 (1995).
232. Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F, Arencibia JM. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Lett. 171(1), 37-45 (2001). (Pubitemid 32727354)
233. Chekhun VF, Lukyanova NY, Urchenko OV, Kulik GI. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Exp. Oncol. 27(3), 191-195 (2005). (Pubitemid 41585956)
234. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr. Relat. Cancer 12(2), 407-421 (2005). (Pubitemid 40896455)
235. Doherty JK, Bond CT, Hua W, Adelman JP, Clinton GM. An alternative HER-2/neu transcript of 8 kb has an extended 3'UTR and displays increased stability in SKOV-3 ovarian carcinoma cells. Gynecol. Oncol. 74(3), 408-415 (1999). (Pubitemid 29439881)
236. Douglas TH, Morgan TO, McLeod DG et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer 80(1), 107-114 (1997). (Pubitemid 27270926)
237. Edwards J, Bartlett JM. Induction of apoptosis and inhibition of cellular proliferation as a dual approach to treatment of ovarian cancer. Int. J. Oncol. 15(3), 583-588 (1999).
238. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int. J. Cancer 78(3), 331-337 (1998). (Pubitemid 28445371)
239. Ferrandina G, Scambia G, Benedetti Panici P et al. Effects of dexamethasone on the growth and epidermal growth factor receptor expression of the OVCA 433 ovarian cancer cells. Mol. Cell. Endocrinol. 83(2-3), 183-193 (1992).
240. Gercel-Taylor C, Taylor DD. Effect of patient-derived lipids on in vitro expression of oncogenes by ovarian tumor cells. Gynecol. Obstet. Invest. 42(1), 42-48 (1996). (Pubitemid 26232470)
241. Grunt TW, Oeller H, Somay C et al. Modulation of the immunophenotype of ovarian cancer cells by N,N-dimethylformamide and transforming growth factor-beta 1. J. Cell Physiol. 156(2), 358-366 (1993). (Pubitemid 23244100)
242. Grunt TW, Puckmair K, Tomek K, Kainz B, Gaiger A. An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells. Biochem. Biophys. Res. Commun. 329(4), 1253-1259 (2005). (Pubitemid 40568704)
243. Grunt TW, Somay C, Oeller H, Dittrich E, Dittrich C. Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J. Cell. Sci. 103 (Pt 2), 501-509 (1992).
244. Guo XN, Zhong L, Tan JZ et al. In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects. Cancer Biol. Ther. 4(10), 1125-1132 (2005). (Pubitemid 41598569)
245. Guo XN, Zhong L, Zhang XH et al. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim. Biophys. Acta 1673(3), 186-193 (2004). (Pubitemid 38981772)
246. Hartmann F, Horak EM, Cho C et al. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2- positive malignant cell lines. Int. J. Cancer 70(2), 221-229 (1997). (Pubitemid 27107421)
247. Hsieh SS, Malerczyk C, Aigner A, Czubayko F. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int. J. Cancer 86(5), 644-651 (2000). (Pubitemid 30249874)
248. Hua W, Christianson T, Rougeot C, Rochefort H, Clinton GM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J. Steroid Biochem. Mol. Biol. 55(3-4), 279-289 (1995). (Pubitemid 26022200)
249. Jeschke M, Wels W, Dengler W, Imber R, Stocklin E, Groner B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer 60(5), 730-739 (1995).
250. Johnson AC, Murphy BA, Matelis CM et al. Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol. Med. 6(1), 17-27 (2000).
251. Jones J, Lagasse LD, Karlan BY. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Gynecol. Oncol. 55(3 Pt 1), 421-426 (1994).
252. Juhl H, Downing SG, Wellstein A, Czubayko F. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER- 2/neu by ribozyme targeting. J. Biol. Chem. 272(47), 29482-29486 (1997).
253. Kao MC, Liu GY, Chuang TC, Lin YS, Wuu JA, Law SL. The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. Oncogene 16(4), 547-554 (1998).
254. Karlan BY, Jones J, Slamon DJ, Lagasse LD. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol. Oncol. 53(1), 70-77 (1994). (Pubitemid 24136905)
255. King BL, Carter D, Foellmer HG, Kacinski BM. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am. J. Pathol. 140(1), 23-31 (1992).
256. Klutchko SR, Hamby JM, Boschelli DH et al. 2-Substituted aminopyrido[2,3-d]pyrimidin- 7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. 41(17), 3276-3292 (1998). (Pubitemid 28376533)
257. Lee H, Maihle NJ. Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell lines and normal human tissues. Oncogene 16(25), 3243-3252 (1998). (Pubitemid 28330422)
258. Lui VW, He Y, Huang L. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol. Ther. 3(2), 169-177 (2001). (Pubitemid 32509819)
259. Marth C, Lang T, Cronauer MV et al. Epidermal growth factor reduces HER-2 protein level in human ovarian carcinoma cells. Int. J. Cancer 52(2), 311-316 (1992).
260. Provencher DM, Lounis H, Champoux L et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev. Biol. Anim. 36(6), 357-361 (2000). (Pubitemid 30626747)
261. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am. J. Obstet. Gynecol. 164(3), 745-750 (1991).
262. Rodriguez GC, Boente MP, Berchuck A et al. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am. J. Obstet. Gynecol. 168(1 Pt 1), 228-232 (1993). (Pubitemid 23047645)
263. Scoles DR, Pavelka J, Cass I et al. Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecol. Oncol. 104(1), 120-128 (2007). (Pubitemid 46075143)
264. Simpson BJ, Bartlett JM, Macleod KG et al. Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868. Br. J. Cancer 79(7-8), 1098-1103 (1999). (Pubitemid 29087881)
265. Stromberg K, Collins TJT, Gordon AW, Jackson CL, Johnson GR. Transforming growth factor-alpha acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res. 52(2), 341-347 (1992).
266. Tang P, Hung MC, Klostergaard J. TNF cytotoxicity: effects of HER-2/neu expression and inhibitors of ADP-ribosylation. Lymphokine Cytokine Res. 13(2), 117-123 (1994). (Pubitemid 24136352)
267. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 60(18), 5310-5317 (2000).
268. Wiechen K, Karaaslan S, Dietel M. Involvement of the c-erbB-2 oncogene product in the EGF-induced cell motility of SK-OV-3 ovarian cancer cells. Int. J. Cancer 83(3), 409-414 (1999). (Pubitemid 29455766)
269. Witters L, Kumar R, Mandal M, Bennett CF, Miraglia L, Lipton A. Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res. Treat. 53(1), 41-50 (1999). (Pubitemid 29123618)
270. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC Jr. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin. Cancer Res. 5(11), 3653-3660 (1999).
271. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53(4), 891-898 (1993). (Pubitemid 23077880)
272. Sedlak J, McGown A, Hrubisko M, Hunakova L, Chorvath B. Drug-resistance associated alterations of cell surface antigen expression in a human anthracycline-resistant ovarian carcinoma cell line. Neoplasma 41(5), 259-262 (1994). (Pubitemid 24324130)
273. Arencibia JM, Schally AV, Krupa M et al. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int. J. Oncol. 19(3), 571-577 (2001).
274. Kammerer U, Thanner F, Kapp M, Dietl J, Sutterlin M. Expression of tumor markers on breast and ovarian cancer cell lines. Anticancer Res. 23(2A), 1051-1055 (2003). (Pubitemid 36750918)
275. Kutteh WH, Miller DS, Mathis JM. Immunologic characterization of tumor markers in human ovarian cancer cell lines. J. Soc. Gynecol. Investig. 3(4), 216-222 (1996). (Pubitemid 26242816)
276. Zhou L, Leung BS. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1. Biochim. Biophys. Acta 1180(2), 130-136 (1992).
277. Christen RD, Hom DK, Porter DC et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest. 86(5), 1632-1640 (1990). (Pubitemid 20372614)
278. Sain N, Krishnan B, Ormerod MG et al. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol. Cancer Ther. 5(5), 1197-1208 (2006). (Pubitemid 43881312)
279. Bartholomeusz C, Oishi T, Saso H et al. MEK 1/2 Inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol. Cancer Ther. 11(2), 360-369 (2011).
280. Brunner-Kubath C, Shabbir W, Saferding V et al. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res. Treat. 129(2), 387-400 (2011).
281. Fujimura M, Katsumata N, Tsuda H et al. HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J. Cancer Res. 93(11), 1250-1257 (2002). (Pubitemid 36032989)
282. Haluska P, Carboni JM, TenEyck C et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 7(9), 2589-2598 (2008).
283. Luistro 3rd LL, Tovar C, Bishayee S, Rameshwar P, Ponzio NM, Ritland SR. Development and characterization of a pre clinical model of ovarian carcinoma to investigate mechanisms of resistance to the anti-HER2/neu antibody herceptin. Proc. Am. Assoc. Cancer Res. 45, 1205 (2004).
284. Pack SD, Alper OM, Stromberg K et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res. 64(3), 789-794 (2004). (Pubitemid 38176872)
285. Yanagibashi T, Gorai I, Nakazawa T et al. Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br. J. Cancer 76(7), 829-835 (1997). (Pubitemid 27401931)